scholarly journals Viral load versus CD4+ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa

AIDS ◽  
2014 ◽  
Vol 28 (16) ◽  
pp. 2451-2460 ◽  
Author(s):  
Luisa Salazar-Vizcaya ◽  
Olivia Keiser ◽  
Karl Technau ◽  
Mary-Ann Davies ◽  
Andreas D. Haas ◽  
...  
Keyword(s):  
Viral Load ◽  
Antiretroviral Therapy ◽  
Southern Africa ◽  
Hiv Positive

scholarly journals Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda

PLoS ONE ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. e0246140
Author(s):  
Sarah Nabukeera ◽  
Joseph Kagaayi ◽  
Fredrick Edward Makumbi ◽  
Henry Mugerwa ◽  
Joseph K. B. Matovu
Keyword(s):  
Viral Load ◽  
Antiretroviral Therapy ◽  
Side Effects ◽  
Clinical Research ◽  
Clinical Stage ◽  
Research Centre ◽  
Hiv Positive ◽  
Factors Associated ◽  
Art Initiation ◽  
Stage 4

Background While the proportion of HIV-positive children (under 15 years) enrolled on antiretroviral therapy (ART) has increased in recent years, up to 60% of children started on ART do not achieve virological suppression. We set out to determine the factors associated with virological non-suppression among children living with HIV receiving ART at a peri-urban HIV care clinic in Kampala, Uganda. Method This was a retrospective cohort study conducted at the pediatric HIV/AIDS clinic at the Joint Clinical Research Centre (JCRC) in Kampala, Uganda. Three hundred (300) HIV-positive children (0–14 years) were randomly selected from existing medical records and data on children’s socio-demographic and clinical characteristics (age at ART initiation, WHO clinical staging, and ART-induced side effects) were abstracted using a data abstraction form. Virological non-suppression was defined as a viral load ≥1000 copies/Ml of blood after six months of ART initiation. Incident rate ratios (IRRs) were determined as a measure of association between virological non-suppression and child/patient characteristics. The IRRs were obtained via a modified Poisson regression with corresponding 95% confidence intervals (95%CI). All analyses were done using statistical package, Stata version 15. Results The overall non-suppression rate among HIV-positive children on ART was 23%. Being at WHO clinical stage 4 at ART initiation [adj. IRR 2.74; 95%CI: 1.63, 4.61] and ART-induced side effects [adj. IRR 1.77; 95%CI: 1.06, 2.97] were significantly associated with non-suppression. Older age at ART initiation (age 5–9 years: [adj. IRR 0.42; 95%CI: 0.28, 0.65]; age 10–14 years: [adj. IRR 0.34; 95%CI: 0.18, 0.64] was less likely to be associated with virological non-suppression. Conclusion Nearly a quarter of HIV-positive children on ART had a non-suppressed viral load after six months of treatment. Being at WHO clinical stage 4 at ART initiation and ART-induced side effects were significantly associated with virological non-suppression while older age at ART initiation was protective. Our findings suggest a need for age-specific interventions, particularly those targeting children below five years of age, to improve virological suppression among HIV-positive children receiving ART in this setting.

Association between atazanavir plasma levels and renal function in HIV-positive individuals on antiretroviral therapy with undetectable viral load

2013 ◽  
Vol 41 (5) ◽  
pp. 497-498
Author(s):  
Ana Júlia Luz ◽  
Júlia Poeta ◽  
Rafael Linden ◽  
Marina Venzon Antunes ◽  
Luiza Isola Caminha ◽  
...  
Keyword(s):  
Renal Function ◽  
Viral Load ◽  
Antiretroviral Therapy ◽  
Plasma Levels ◽  
Undetectable Viral Load ◽  
Hiv Positive

scholarly journals Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Bradley T. Williamson ◽  
Heather A. Leitch
Keyword(s):  
Bone Marrow ◽  
Viral Load ◽  
Antiretroviral Therapy ◽  
Myelodysplastic Syndromes ◽  
Hiv Positive ◽  
Combination Antiretroviral Therapy ◽  
Hiv Viral Load ◽  
Hiv Patients ◽  
Age Of Diagnosis ◽  
Hiv Negative

Introduction. In advanced HIV prior to combination antiretroviral therapy (ART), dysplastic marrow changes occurred and resolved with ART. Few reports of myelodysplastic syndromes (MDS) in well-controlled HIV exist and management is undefined.Methods. Patients with well-controlled HIV and higher risk MDS were identified; characteristics, treatment, and outcomes were reviewed.Results. Of 292 MDS patients since 1996, 1 (0.3%) was HIV-positive. A 56-year-old woman presented with cytopenias. CD4 was 1310 cells/mL and HIV viral load <40 copies/mL. Bone marrow biopsy showed RCMD and karyotype included del(5q) and del(7q); IPSS was intermediate-2 risk. She received azacitidine at 75% dose. Cycle 2, at full dose, was complicated by marrow aplasia and possible AML; she elected palliation. Three additional HIV patients with higher risk MDS, aged 56–64, were identified from the literature. All had deletions involving chromosomes 5 and 7. MDS treatment of 2 was not reported and one received palliation; all died of AML.Conclusion. Four higher risk MDS in well-controlled HIV were below the median age of diagnosis for HIV-negative patients; all had adverse karyotype. This is the first report of an HIV patient receiving MDS treatment with azacitidine. Cytopenias were profound and dosing in HIV patients should be considered with caution.

scholarly journals Validation of the Viral Load Testing Criteria – an algorithm for targeted viral load testing in HIV‐positive adults receiving antiretroviral therapy

2019 ◽  
Vol 24 (3) ◽  
pp. 356-362
Author(s):  
Johannes Thorman ◽  
Per Björkman ◽  
Fregenet Tesfaye ◽  
Asiya Jeylan ◽  
Taye Tolera Balcha ◽  
...  
Keyword(s):  
Viral Load ◽  
Antiretroviral Therapy ◽  
Hiv Positive ◽  
Load Testing ◽  
Viral Load Testing ◽  
Hiv Positive Adults ◽  
Testing Criteria

scholarly journals Baseline Clinical Characteristics, Antiretroviral Therapy Use, and Viral Load Suppression Among HIV-Positive Young Men of Color Who Have Sex with Men

2011 ◽  
Vol 25 (S1) ◽  
pp. S9-S14 ◽  
Author(s):  
Lisa B. Hightow-Weidman ◽  
Karen Jones ◽  
Gregory Phillips ◽  
Amy Wohl ◽  
Thomas P. Giordano, for The YMSM of Color SPN
Keyword(s):  
Viral Load ◽  
Antiretroviral Therapy ◽  
Clinical Characteristics ◽  
Young Men ◽  
Hiv Positive ◽  
Viral Load Suppression ◽  
Men Of Color ◽  
Sex With Men

scholarly journals Predictors of undetectable plasma viral load in HIV-positive adults receiving antiretroviral therapy in Southern Brazil

2002 ◽  
Vol 6 (4) ◽  
Author(s):  
Marysabel Pinto Telis Silveira ◽  
Maria de Lourdes Draschler ◽  
José Carlos de Carvalho Leite ◽  
Cezar Arthur Tavares Pinheiro ◽  
Vera Lúcia da Silveira
Keyword(s):  
Viral Load ◽  
Antiretroviral Therapy ◽  
Plasma Viral Load ◽  
Hiv Positive ◽  
Southern Brazil ◽  
Undetectable Plasma ◽  
Hiv Positive Adults ◽  
Undetectable Plasma Viral Load

scholarly journals Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Chiara Cecchelli ◽  
Giacomo Grassi ◽  
Stefano Pallanti
Keyword(s):  
Viral Load ◽  
Antiretroviral Therapy ◽  
Immunological Response ◽  
Cd4 Count ◽  
Hiv Positive ◽  
Psychotropic Agents ◽  
Resistant Depression ◽  
Present Case Study ◽  
The Impact

Aripiprazole is the first medication approved by the FDA as an add-on treatment for MDD. The impact of aripiprazole on the response to HIV is unknown. The patient we report on was diagnosed HIV-positive in 1997 and has been treated with antiretroviral therapy since then. In 2008, we diagnosed resistant major depression, hypochondria, and panic disorder. On that occasion, blood tests showed a significantly reduced CD4 count and a positive viral load. We treated this patient with aripiprazole and citalopram. Mood, somatic symptoms, and occupational functioning progressively improved. The last blood examination showed an increase in the CD4 count and a negative viral load. On the basis of the present case study and the review of the literature concerning the effects of psychotropic agents on viral replication, we suggest that the use of aripiprazole in HIV-infected subjects warrants further research.

Sign in / Sign up

Export Citation Format

Share Document